Engeletin alleviates depression‐like phenotype by increasing synaptic plasticity via the BDNF‐TrkB‐mTORC1 signalling pathway
Open Access
- 6 October 2023
- journal article
- research article
- Published by Wiley in Journal of Cellular and Molecular Medicine
- Vol. 27 (23) , 3928-3938
Abstract
Major depressive disorder (MDD) is a severe mental disorder associated with high rates of morbidity and mortality. Current first‐line pharmacotherapies for MDD are based on enhancement of monoaminergic neurotransmission, but these antidepressants are still insufficient and produce significant side‐effects. Consequently, the development of novel antidepressants and therapeutic targets is desired. Engeletin, a natural Smilax glabra rhizomilax derivative, is a compound with proven efficacy in treating ischemic stroke, yet its therapeutic effects and mechanisms for depression remain unexplored. The effects of engeletin were assessed in the forced swimming test (FST) and tail suspension test (TST) in mice. Engeletin was also investigated in the chronic restraint stress (CRS) mouse model of depression with fluoxetine (FLX) as the positive control. Changes in prefrontal cortex (PFC) spine density, synaptic plasticity‐linked protein expressions and the brain‐derived neurotrophic factor (BDNF)‐tyrosine kinase B (TrkB)‐ mammalian target of rapamycin complex 1 (mTORC1) signalling pathway after chronic stress and engeletin treatment were then investigated. The TrkB and mTORC1 selective inhibitors, ANA‐12 and rapamycin, respectively, were utilized to assess the engeletin's antidepressive mechanisms. Our data shows that engeletin exhibited antidepressant‐like activity in the FST and TST in mice without affecting locomotor activity. Furthermore, it exhibited efficiency against the depression of CRS model. Moreover, it enhanced the BDNF‐TrkB‐mTORC1 pathway in the PFC during CRS and altered the reduction in dendritic spine density and levels of synaptic plasticity‐linked protein induced by CRS. In conclusion, engeletin has antidepressant activity via activation of the BDNF‐TrkB‐mTORC1 signalling pathway and upregulation of PFC synaptic plasticity.Keywords
This publication has 40 references indexed in Scilit:
- Liquiritigenin reverses depression-like behavior in unpredictable chronic mild stress-induced mice by regulating PI3K/Akt/mTOR mediated BDNF/TrkB pathwayBehavioural Brain Research, 2016
- Stress-induced structural plasticity of medial amygdala stellate neurons and rapid prevention by a candidate antidepressantMolecular Psychiatry, 2016
- Antidepressant Effects of TrkB Ligands on Depression-Like Behavior and Dendritic Changes in Mice After InflammationInternational Journal of Neuropsychopharmacology, 2015
- Synaptic plasticity in depression: Molecular, cellular and functional correlatesProgress in Neuro-Psychopharmacology and Biological Psychiatry, 2013
- Chronic restraint stress causes anxiety- and depression-like behaviors, downregulates glucocorticoid receptor expression, and attenuates glutamate release induced by brain-derived neurotrophic factor in the prefrontal cortexProgress in Neuro-Psychopharmacology and Biological Psychiatry, 2012
- Increasing the validity of experimental models for depressionAnnals of the New York Academy of Sciences, 2012
- Effect of chronic intermittent restraint stress on hippocampal expression of marker proteins for synaptic plasticity and progenitor cell proliferation in ratsBrain Research, 2005
- Stress, depression, and anhedonia: Caveats concerning animal modelsNeuroscience & Biobehavioral Reviews, 2005
- Potentiation of 5-HT3 receptor function by the activation of coexistent 5-HT2 receptors in trigeminal ganglion neurons of ratsNeuropharmacology, 2004
- How valuable are animal models in defining antidepressant activity?Human Psychopharmacology: Clinical and Experimental, 2001